Innox Spółka z Ograniczoną Odpowiedzialnością (KRS 0000820366, NIP 9662135821) is a Polish company, headquartered in Białystok, Podlaskie voivodeship. INNOX operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 20, 2019. INNOX's most recently reported net revenue was 19.2 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Innox
Identity
- Name
- Innox Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 20, 2019
- Registry status as of
- November 21, 2025
- Latest entry
- July 3, 2025
- Founding act
- 17.12.2019 R.
Articles of association history (2)
- December 17, 2019: 17.12.2019 R.
- July 30, 2021: 30.07.2021, REPERTORIUM A NR 3758/2021, NOTARIUSZ MAŁGORZATA ROSMAN; KANCELARIA NOTARIALNA MAŁGORZATA ROSMAN WANDA WOJEWODA S.C., UL. MARSZAŁKOWSKA 83/29, 00-683 WARSZAWA; ZMIENIONO: §1, §2, §3, §4, §5, §6, §7, §8, §9, §10, §11, §12, §13, §14, §15, §16, §17 UMOWY SPÓŁKI; PRZYJĘTO TEKST JEDNOLITY UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. ŻURAWIA, 71, 15-540, BIAŁYSTOK, POLSKA
- Voivodeship
- PODLASKIE
- District
- BIAŁYSTOK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-81877-18223-GIAVT-28
- Coordinates
- 53.1322, 23.1588approx.
Risk and payment profile - Innox
Credibility rating
25.9 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
37
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/6 yrs
Board changes
1
1/6 yrs
PKD changes
0
0/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: E (26/100)
Trend: stable (-1.2 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2020–2024
Current: 992.0 K PLN
Safe: 138.9 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Innox
Founded
December 20, 2019
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
BIAŁYSTOK
PODLASKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
6.0 M PLN
Shareholders
1
shareholder
Board
1 person
Filed years
5 years
2020–2024 · profitable: 0/5
Registry entries
21
latest: July 3, 2025
Risk signals
Revenue
19.2 K PLN
2024
Net profit
-1.5 M PLN
2024
Assets
12.3 M PLN
2024
Equity
136.7 K PLN
2024
EBITDA
-1.4 M PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Innox.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
